C15ORF48 serves as a potential biomarker and therapeutic target in pan-cancer with implications for lung cancer

Lung cancer ranks among the top causes of cancer-related deaths globally. Prompt diagnosis and timely intervention play a vital role in enhancing patient prognosis and increasing survival chances. Although C15ORF48 expression is generally elevated in tumor tissues, it is reduced in specific cancers like colorectal cancer, and its role across pan-cancer remains unclear. This research investigates the expression, immune infiltration, and predictive significance of C15ORF48 in pan-cancer using multiple databases, including TIMER2.0, GEPIA, and the Human Protein Atlas. Additionally, we use cBioPortal, PhosphoNET, and AlphaFold to analyze the distribution of genetic alterations, phosphorylation sites, and pathogenic hotspots in C15ORF48. C15ORF48 expression is generally elevated in tumor versus normal tissues, and its distribution in lung tissues is predominantly cytoplasmic. C15ORF48 expression is positively correlated with the level of expression shows a positive association with the degree of CD8 + T cell infiltration.,etc. Furthermore, higher C15ORF48 expression is associated with poorer survival in lung adenocarcinoma, etc. Genetic alterations in C15orf48, including S29F, T38I, and K61N, and predicted phosphorylation sites such as S28, S29, T38, and T53, are identified across various cancers. Additionally, pathogenic hotspots, including G25D, S28K, and T38W, are highlighted. The results indicate that C15ORF48 could play a significant role in pan-cancer, particularly in lung cancer, and may serve as a potential biomarker for prognosis and targeted therapies.